Wedbush initiated coverage of Cullinan Oncology with an Outperform rating and $30 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CGEM:
- Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
- Cullinan Oncology says first patient dosed with CLN-617 in Phase 1 trial